Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

(2022) Mônica Gadelha et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing’s Syndrome Treatment

(2021) Sara G Creemers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored

(2021) Frederic Castinetti et al.   CLINICAL ENDOCRINOLOGY

Consensus on diagnosis and management of Cushing's disease: a guideline update

(2021) Maria Fleseriu et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

(2020) Rosario Pivonello et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

(2019) Maria Fleseriu et al.   Lancet Diabetes & Endocrinology

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

(2015) Maria Fleseriu et al.   Pituitary